SCHEDULE: Glenview Capital Discloses 5.3% Stake in Myriad Genetics

Glenview Capital Management and Larry Robbins have reported a 5.3% passive beneficial ownership stake in Myriad Genetics Inc. common stock.

Summary

• Glenview Capital Management, LLC and Larry Robbins (collectively, the "Reporting Persons") have filed a Schedule 13G.
• They beneficially own an aggregate of 4,941,058 shares of Myriad Genetics Inc. Common Stock.
• This represents approximately 5.3% of the 93,213,722 outstanding shares of Myriad Genetics Inc. as of October 31, 2025.
• The shares are held across Glenview Capital Master Fund (1,886,965 shares), Glenview Offshore Opportunity Master Fund (2,791,657 shares), and Glenview Healthcare Master Fund (262,436 shares).
• The filing certifies that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer.

Sentiment

Score: 6

Explanation: The disclosure of a significant passive stake by a reputable institutional investor like Glenview Capital Management is generally viewed as a positive signal, indicating confidence in the company's value, though it doesn't provide operational or financial performance details.

Positives

• A significant institutional investor, Glenview Capital Management, has taken a 5.3% passive stake in Myriad Genetics, potentially signaling confidence in the company's long-term prospects and valuation.

Negatives

• NA

Risks

• The filing does not detail specific risks related to Myriad Genetics Inc.; it is a disclosure of beneficial ownership.

Future Outlook

This filing does not contain forward-looking statements or guidance from the issuer.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11."

Industry Context

Schedule 13G filings are routine disclosures by institutional investors who acquire more than 5% of a company's stock with a passive investment intent. For Myriad Genetics, a company in the healthcare/biotechnology sector, a significant stake by a prominent fund like Glenview Capital Management can be viewed as a positive signal regarding the company's valuation or future prospects within its industry.

Stakeholder Impact

• Shareholders: The disclosure of a significant passive stake by a major institutional investor could instill confidence and potentially attract further investor interest, positively impacting share price.
• Management: While the stake is passive, management may view this as a vote of confidence from a sophisticated investor.

Key Dates

Recommendation

While the disclosure of a significant passive stake by a reputable institutional investor like Glenview Capital Management is generally a positive indicator, a Schedule 13G filing alone does not provide enough fundamental information about Myriad Genetics' operational performance, financial health, or strategic direction to warrant a 'buy' or 'sell' recommendation. It primarily signals an investor's belief in the company's value at the current price, suggesting a 'hold' position until further financial or strategic updates are available.

Keywords

Myriad Genetics, Glenview Capital Management, Larry Robbins, Schedule 13G, beneficial ownership, common stock, institutional investment, healthcare, biotechnology